Amivantamab vs real-world (RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i)

被引：0
|
作者：
Kim, T. M. [1 ]
Girard, N. [2 ]
Low, G. K. M. [3 ]
Zhuo, J. [4 ]
Yu, D. Y. [5 ]
Yang, Y. [4 ]
Murota, M. [6 ]
Lim, C. [7 ]
Kleinman, N. J. [8 ]
Cho, B. C. [9 ]
机构：
[1] Seoul Natl Univ Hosp, Hemato Oncol, Seoul, South Korea
[2] Inst Curie, Thorax Inst, Paris, France
[3] Janssen Asia Pacific, Med Affairs, Singapore, Singapore
[4] Janssen China, Res & Dev, Shanghai, Peoples R China
[5] Janssen Asia Pacific, Real World Evidence, Singapore, Singapore
[6] Janssen Res & Dev, Med Affair Operat, Global Dev, Tokyo, Japan
[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore
[8] IQVIA Hong Kong, Real World Solut, Hong Kong, Peoples R China
[9] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Med Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1109p
引用
收藏
页码：S1058 / S1058
页数：1
相关论文
共 50 条
  • [21] Clinical and real-world outcomes in patients with epidermal growth factor receptor (EGFR) exon 20 insertions in non-small cell lung cancer (NSCLC): A meta-analysis
    Tomaras, D.
    Lin, H. M.
    Forsythe, A.
    Crossland, V.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2020, 31 : S871 - S871
  • [22] An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
    Christos Chouaid
    Lise Bosquet
    Nicolas Girard
    Anna Kron
    Matthias Scheffler
    Frank Griesinger
    Martin Sebastian
    Jose Trigo
    Santiago Viteri
    Craig Knott
    Bernardo Rodrigues
    Nora Rahhali
    Jedelyn Cabrieto
    Joris Diels
    Nolen J. Perualila
    Claudio A. Schioppa
    Jan Sermon
    Raphael Toueg
    Nicole Erdmann
    Janka Mielke
    Mehregan Nematian-Samani
    Cristina Martin-Fernandez
    Innocent Pfaira
    Tracy Li
    Parthiv Mahadevia
    Jürgen Wolf
    Advances in Therapy, 2023, 40 : 1187 - 1203
  • [23] Advanced Non Small Cell Lung Cancer With EGFR Exon 20 Insertion Gene Mutation
    Lam, N. S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S510 - S510
  • [24] A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Christos Chouaid
    Thomas Filleron
    Didier Debieuvre
    Maurice Pérol
    Nicolas Girard
    Eric Dansin
    Hervé Lena
    Radj Gervais
    Sophie Cousin
    Josiane Otto
    Roland Schott
    David Planchard
    Anne Madroszyk
    Courèche Kaderbhai
    Pascale DUBRAY-Longeras
    Sandrine Hiret
    Eric Pichon
    Christelle Clément-Duchêne
    Gaëlle Chenuc
    Gaëtane Simon
    Lise Bosquet
    Xavier QUantin
    Targeted Oncology, 2021, 16 : 801 - 811
  • [25] A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
    Chouaid, Christos
    Filleron, Thomas
    Debieuvre, Didier
    Perol, Maurice
    Girard, Nicolas
    Dansin, Eric
    Lena, Herve
    Gervais, Radj
    Cousin, Sophie
    Otto, Josiane
    Schott, Roland
    Planchard, David
    Madroszyk, Anne
    Kaderbhai, Coureche
    Dubray-Longeras, Pascale
    Hiret, Sandrine
    Pichon, Eric
    Clement-Duchene, Christelle
    Chenuc, Gaelle
    Simon, Gaetane
    Bosquet, Lise
    QUantin, Xavier
    TARGETED ONCOLOGY, 2021, 16 (06) : 801 - 811
  • [26] Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
    Sabari, J. K.
    Shu, C. A.
    Park, K.
    Leighl, N.
    Mitchell, P.
    Kim, S.
    Lee, J.
    Kim, D.
    Viteri, S.
    Spira, A.
    Han, J.
    Trigo, J.
    Lee, C. K.
    Lee, K. H.
    Girard, N.
    Yang, T.
    Goto, K.
    Sanborn, R. E.
    Yang, J. C.
    Xie, J.
    Roshak, A.
    Thayu, M.
    Knoblauch, R. E.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S108 - S109
  • [27] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Sa, Huanlan
    Shi, Yan
    Ding, Chunxia
    Ma, Kewei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (10) : 7729 - 7742
  • [28] A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
    Huanlan Sa
    Yan Shi
    Chunxia Ding
    Kewei Ma
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 7729 - 7742
  • [29] Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer
    Haddish-Berhane, Nahor
    Su, Yaming
    Russu, Alberto
    Thayu, Meena
    Knoblauch, Roland E.
    Mehta, Jaydeep
    Xie, John
    Gibbs, Eric
    Sun, Yu-Nien
    Zhou, Honghui
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (03) : 468 - 477
  • [30] FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Chon, Katie
    Larkins, Erin
    Chatterjee, Somak
    Mishra-Kalyani, Pallavi S.
    Aungst, Stephanie
    Wearne, Emily
    Subramaniam, Sriram
    Li, Yangbing
    Liu, Jiang
    Sun, Jielin
    Charlab, Rosane
    Zhao, Hong
    Saritas-Yildirim, Banu
    Bikkavilli, Rama Kamesh
    Ghosh, Soma
    Philip, Reena
    Beaver, Julia A.
    Singh, Harpreet
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3262 - 3266
12345